Podcasts about mg

- 2027 Chevy Bolt Gets Mild Facelift - China Resumes Magnet Exports, To A Degree - BYD's Sales Growth Stalls Out - Neta and Zeekr Fudge Sales Numbers - Stellantis To Report Q2 Loss Of €2.5B  - Tata Wants to Buy Iveco - U.S. Car Dealers Q2 Profits +27%  - MG Claims Semi-Solid Battery Debuts Next Month - Mercedes Slashes EV Prices - Autoline Poll on Direct Sales

- 2027 Chevy Bolt Gets Mild Facelift - China Resumes Magnet Exports, To A Degree - BYD's Sales Growth Stalls Out - Neta and Zeekr Fudge Sales Numbers - Stellantis To Report Q2 Loss Of €2.5B  - Tata Wants to Buy Iveco - U.S. Car Dealers Q2 Profits +27%  - MG Claims Semi-Solid Battery Debuts Next Month - Mercedes Slashes EV Prices - Autoline Poll on Direct Sales

O Camisa 10 deste sábado falará tudo sobre os jogos deste fim de semana no Brasileirão. Hoje tem o clássico São Paulo x Corinthians no Morumbi! Amanhã, por sua vez, Flamengo e Fluminense se enfrentam no Maracanã, e o Palmeiras encara o Atlético-MG dentro de casa. Learn more about your ad choices. Visit megaphone.fm/adchoices

“Dipsticks, Bribes & Bad Booze: Life in the Lemons Judge's Chair | Everyone Racers Podcast EP 396”In this hilarious and chaotic SS 396 episode of the Everyone Racers Podcast, the gang dives deep into the wild world of Lemons judging—complete with Chevelles, MG propaganda, Cadillac neck tattoos, and dollar store meat thermometers.

Martine Hackett returns with a new season of Untold Stories: Life with a Severe Autoimmune Condition. The best stories unite us, empower us, and help us push forward against all odds. This season, we hear from people living with myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP) as they reclaim their identities, fight for care, and find strength in both community and themselves. Join us starting July 23rd.See omnystudio.com/listener for privacy information.

Para falar sobre o avanço da mineração no Vale do Jequitinhonha (MG), neste episódio, entrevistamos Jean Freire, deputado estadual pelo Partido dos Trabalhadores (PT) e vice-líder do bloco Democracia e Luta na ALMG. "Eu sempre cito o livro Veias Abertas da América Latina, que diz que a mineração trouxe para Minas Gerais e para o Brasil buracos, igrejas para Portugal, e riqueza e indústrias para a Inglaterra. Hoje, o lítio traz indústrias para fora, igrejas para lugar nenhum, e buracos para MG. Nós vamos ficar com os buracos?", questionou Jean Freire. Confira a entrevista completa.

In this episode we talk with mg (https://x.com/MG), the brilliant (and notorious) hacker and hardware engineer behind the OMG Cable. A seemingly ordinary USB cable with extraordinary offensive capabilities.Learn more about mg at: o.mg.lolSponsorsSupport for this show comes from ThreatLocker®. ThreatLocker® is a Zero Trust Endpoint Protection Platform that strengthens your infrastructure from the ground up. With ThreatLocker® Allowlisting and Ringfencing™, you gain a more secure approach to blocking exploits of known and unknown vulnerabilities. ThreatLocker® provides Zero Trust control at the kernel level that enables you to allow everything you need and block everything else, including ransomware! Learn more at www.threatlocker.com.Support for this show comes from Axonius. The Axonius solution correlates asset data from your existing IT and security solutions to provide an always up-to-date inventory of all devices, users, cloud instances, and SaaS apps, so you can easily identify coverage gaps and automate response actions. Axonius gives IT and security teams the confidence to control complexity by mitigating threats, navigating risk, decreasing incidents, and informing business-level strategy — all while eliminating manual, repetitive tasks. Visit axonius.com/darknet to learn more and try it free.

Do pałacu wchodzi niziołek, gnom i Tileańczyk wychowany przez Strzygan... Brzmi jak początek dowcipu, ale w świecie Warhammera to się rzeczywiście wydarzyło. Co prawda w różnym czasie, ale postaci te łączyło to, że wszyscy oni byli błaznami. Dziś Werner przyjrzy się właśnie temu, co wiemy o ludziach, którzy swoje życie poświęcili temu, by zabawiać innych. Nie tylko na dworach rodzin panujących, ale też na szlakach Starego Swiata.------------------------------------------------------------

A volta do Campeonato Brasileiro não trouxe novidades na caminhada de Bahia e Vitória. O Tricolor fez mais um vez a sua parte, venceu o Atlético-MG e subiu para o G-4 da competição. Já o Rubro-Negro decepcionou novamente, desta vez na estreia de Fábio Carille, perdeu para o Internacional e voltou para a zona de rebaixamento. Programa debate as atuações das equipes, o Tricolor de olho em novo goleiro e o que esperar dos próximos jogos.

#217. O lendário personagem Cascão, da Turma da Mônica, finalmente entrou na água? Neste podcast, Alexander Turra, coordenador da Cátedra UNESCO para a Sustentabilidade do Oceano, fala sobre a revista em quadrinhos lançada recentemente. O tema central da publicação é, justamente, esse ecossistema vital à humanidade. E será que o personagem de Maurício de Souza não resistiu ao banho (de mar)? Brincadeiras à parte, o gibi está lindo, e pode ser baixado em formato PDF, através do link: https://catedraoceano.iea.usp.br/turmadamonica/Você pode enviar um e-mail à Cátedra UNESCO para a Sustentabilidade do Oceano e pedir um exemplar, gratuito. Basta escrever para o seguinte endereço eletrônico: catedraoceano@iea.usp.brConheça mais sobre a Cátedra UNESCO para a Sustentabilidade do Oceano: https://catedraoceano.iea.usp.br/Ainda não ouviu o primeiro bate-papo com Alexander Turra no Maré Sonora. Acesse aqui:https://youtu.be/mYqHh_xV4ic?si=hKb_aUwBclGPvBAlApoio: Café do Luiz Café artesanal, especial e cultivado no Sudoeste de MG. Entregas para todo o Brasil através dos contatos a seguir: Instagram: https://www.instagram.com/cafedoluiz/ Em São Paulo (11) 99830-0777 Florianópolis (48) 99988-0711

Revoyez avec Pr Darrouzet, les points clefs à retenir concernant les diagnostiques à ne pas louper en pratique quotidienne de MG.Au cours de ce podcast, vous reverrez : ✅ Les drapeaux rouges neurologiques ?✅ Le HINTS test : pourquoi tout MG devrait savoir faire ce test ? Comment le faire en 1 min chrono.✅ Les 4 vertiges les + fréquents qui représentent >90% des cas.✅ Quel matériel acheter ?✅ Quand adresser chez l'ORL ?

Trump ataca o Brasil com tarifas, o povo se levanta pela soberania, e a bomba explode entre bolsonaristas. Quem paga essa conta?A militarização das escolas de MG avança e levanta a pergunta: é essa a educação que queremos?Um novo complexo hospitalar na Gameleira, mas com um detalhe crucial: a administração será privada e outros quatro hospitais podem ser fechados. Benefício ou retrocesso?Este é mais um ENFIM, SEXTA! — seu encontro semanal com a análise crítica, progressista e popular sobre o que acontece em Minas Gerais, no Brasil e no mundo. Conversamos com a deputada estadual Bella Gonçalves (Psol) e o vereador de BH Bruno Pedralva (PT). Confira!

Cat Beast Theme Connie Francis - Pretty Little Baby Andy Williams - The House Of Bamboo The Heavy - Love Like That Annette Funicello & Fishbone - Jamaica Ska Robert Mitchum - Coconut Water Booker T & The MG's - Soul Limbo The Ex-Bombers - He's A Bad Bad Man The Phantom A.D. - Ric Flair Rock Shawn Michaels - Sexy Boy Echo & The Bunnymen - Back Of Love The Exotic Ones - Cat Beast Party The Kinks - Shangri-La The Lovin Spoonful - Summer In The City The Grass Roots - I'd Wait A Million Years The Jokers - Football Boogie The Damned - I Just Can't Be Happy Today Smashing Pumpkins - Today Redd Kross - Where I Am Today The Mooney Suzuki - Singin A Song About Today Mika - Love Today 

Luis hits his 90-day milestone, and in this episode of Learning the Dirt with Luis, he and MG reflect on how far he's come—from learning the ropes to becoming a confident ambassador for safe digging. They recap their visit to the Oklahoma Rural Water Association Expo, talk about the Thunder's championship parade, and even share a story about a possible appearance in an ESPN documentary. Plus, MG walks Luis through how to properly submit a locate request (even for something as simple as planting a tree), and they look ahead to Virtual Safety Day on July 16. It's a fun, informative episode full of laughs, learning, and some big things to come.

W najnowszym odcinku „Rozmów w Dresie” Ania Kolasinska rozmawia z Asią Buraczek – psychoterapeutką i autorką książki Mgła, która odczarowuje mit, że zaburzenia odżywiania to „fanaberia chudzielca z Instagrama”. Asia otwarcie opowiada o własnej anoreksji, hospitalizacji z systemem „nagroda za każdy kilogram” i drodze do zawodu, w którym dziś pomaga pacjentom odzyskać wolność od wagi, liczb i ciągłego lęku. To szczera, pełna metafor rozmowa o tym, że „zacznij jeść” nie leczy, a prawdziwe zdrowienie zaczyna się od pytania „po co mi ta kontrola?”Biowen - https://biowen.eu/?utm_source=youtube.com&utm_medium=paid&utm_campaign=aniakolasinskaszemraj_10_07_2025

Chegou mais um Raio X da Série B do Campeonato Brasileiro. Todas as análises após a 15ª rodada. Um novo Líder, onde tudo podde acontecer, quedas de CRB e Cuiabá, farrapada do América-MG, reação a comentários, odds Betnacional e muito mais! Apresentação de Fred Figueiroa com comentários de Cássio Zirpoli e Hathos Rildo. Na edição, […]

Singles que alcanzaron su puesto más alto en el Billboard Hot 100 en este mismo mes de hace 60 años. Segunda parte dedicada a julio de 1965.(Foto del podcast; Solomon Burke)Playlist;(sintonía) BOOKER T. and THE MG’S “Boot-leg” (top 58)CAL TJADER “Soul sauce (Guacha Guaro)” (top 88)CHET ATKINS “Yaketi axe” (top 98)WILLIE MITCHELL “Buster browne” (top 96)GLORIA LYNNE “Watermelon man” (top 62)LITTLE MILTON “Who’s cheating who?” (top 43)SOLOMON BURKE “Tonight’s the night” (top 28)JOE TEX “One monkey don’t stop no show” (top 65)THE SHANGRI-LAS “Give us your blessings” (top 29)THE CHIFFONS “Nobody knows what's goin' on (in my mind but me)” (top 49)JR. WALKER and THE ALL STARS “Do the boomerang” (top 36)FRED HUGHES “Oo wee baby, I love you” (top 23)CHAD and JEREMY “From a window” (top 97)DONOVAN “Catch the wind” (top 23)MARIANNE FAITHFULL “This little bird” (top 32)OTIS REDDING “I've been loving you too long (to stop now)” (top 21)THE IMPRESSIONS “Meeting over Yonder” (top 48)B.B. KING “Blue shadows” (top 97)FRANK SINATRA “Forget domani” (top 78)Escuchar audio

Quem curte episódio de dicas e ideias por aí? Estamos em pleno mês de julho, e aproveitamos essa oportunidade para lançar um episódio repleto de dicas e ideias de práticas parasuas cenas, sessões e eventos nessa época de ano de Festa de São João, quermesse, festas juninas e julinas, tudo aquilo que a gente tanto ama! Convidamos a Sereia (ou Dom Gustavo), que já esteve conosco no episódio temático de Carnaval, para retornar para mais um brainstorming festivo com a gente, e não faltou criatividade por aqui! Prepara seu bloco de anotações e vem participar dessa conversa divertida com a gente!E aí, vai colocar alguma dessas sugestões em prática? E qual sua forma favorita de consumir milho? Participantes: Ada @aleneouada, Roxy @roxylust, Sereia @domgustavo.gynVoz da vinheta: Midnight Yume de Piraju/SP @delldelovaÁudios: @dionivea @dommekaah @pessoasnaomono @gabidays23 Apoie o Chicotadas! https://apoia.se/chicotadas Form para envio de dúvidas e feedbacks: https://forms.gle/x3HUheP52BkALn989 Nossos links: https://chicotadas.com.br/A vitrine do episódio é uma arte com foto. O fundo é escuro e avermelhado, com padrão de bandeirolas juninas, desenhos de espigas de milho e mais bandeirinhas em vermelho. Do lado esquerdo da arte, uma foto da Sereia (pessoa de gênero fluido branca, que usa barba) montada de caipira, usando peruca loira, vestido com padrão xadrez e floral, segurando um leque.  No canto esquerdo e centro da imagem, o número e título do episódio (#50: Dicas e ideias de práticas: edição festa de São João, com Sereia/Dom Gustavo) em vermelho, lilás e amarelo claro. Na parte superior e inferior da imagem, marca d'água com o arroba do nosso insta @chicotadaspodcast e a logo principal e secundária do podcast. Minutagens:3:00 Introdução do episódio e autodescriçãoEpisódios com Sereia:- Chicotinho 18 (Dúvidas e feedbacks IV)- Episódio 38 (No Bar da Masmorra #04: Sereia/Dom Gustavo)- Episódio 40 (Dicas e ideias de práticas: edição Carnaval)- Clube dos Apoiadores 13 (Papéis e expectativas sociais de gênero no BDSM)5:55 Nossa relação com a festa junina e o universo ruralCitados: QuermesSM, prisão, bondage, algemas, role play/interpretação de papéis, o poder do milho. 19:37 Dicas e ideias de cenas e práticas temáticasCitados: milho, sensation play, food play, sploshing, food crushing, pet play, poney play, cow play, shibari, peia/peiar/laçar, corrida dos subs, interpretação de papel no casamento e papéis tradicionais, hierofilia, montação e looks, caipiranha, chaps, role play de cadeia, bondage, fire play, jogos de temperatura, wax play, correio elegante, decoração, mumificação, gincanas juninas, tiro ao alvo, estilingue e balinhas de goma, CBT, pescaria (anzol = gancho anal), prendedores.Mencionades: Hugo@h.chicotadas, srta g @senhoritagescritora, srta agni @agni.again e as mamonas 51:45 Recado do apoia.se https://apoia.se/chicotadas 54:19 Áudios de apoiadores com histórias e dicas: @dionivea de Guaxupé, MG (ovo na colher, pamonha de ] shibari, cabo de guerra, série Como Criar um quarto do sexo)@dommekaah de Campina Grande, PB (forró, pescaria com knife play, fear play, spanking, olha a corda, flogueira, fire, wax, crush fetish)@pessoasnaomono Poli Vykos de de São José dos Campos (pau de sebo, estalinho, fire play, ambiente rural, pet play de fazenda, role play, primal play de caça) Citado: pig, barraca do spanking, chicote equestre/chibata, sensation play, fear play.@gabidays23 de Curitiba (cow play, ordenha, breath play)1:30:45 Nossas Chicotadas- Estranha forma de vida (Mubi)- Ataque dos cães (Netflix)- Imbilino, Hugo Caiapônia (Youtube)- Chico Bento e a Goiabeira Maraviosa (Prime Video)- Pablo e Luisão (Globo Play)- Nate the hoof guy (TikTok)1:39:00 Conclusão e últimas dicasContatos da Sereia: @domgustavo.gyn (insta), @domgustavo_gyn (Twitter), Sereia (Kinkgram), @bd.sm.gyn (eventos em Goiânia)1:43:54 Despedida e aftercare

Big numbers for Electric Car sales in Australia with a big surge from Tesla and BYD helping it along. Roddy's now a two BYD family with the wife getting a BYD Shark to replace the Prado. And Eliza is thrown onto the show by dad who says she loves her MG

On this episode of Multifamily Mastery, John Casmon interviews Paul Kaseburg, Chief Investment Officer at MG Properties. Paul shares insights into managing a 32,000-unit portfolio across the Western U.S., emphasizing the importance of vertical integration, legislative compliance, and proactive risk management. He details how MG navigates current challenges such as oversupply in multifamily housing, using a value-driven acquisition strategy that balances core-plus and value-add opportunities. Paul also discusses the firm's centralized operational strategies, measured use of AI tools, and the enduring power of company culture and long-term investment planning. Paul Kaseburg Current role: Chief Investment Officer at MG Properties Say hi to them at: mgproperties.com Get a 4-week trial, free postage, and a digital scale at ⁠https://www.stamps.com/cre⁠. Thanks to Stamps.com for sponsoring the show! Post your job for free at https://www.linkedin.com/BRE. Terms and conditions apply. Join the Best Ever Community  The Best Ever Community is live and growing - and we want serious commercial real estate investors like you inside. It's free to join, but you must apply and meet the criteria.  Connect with top operators, LPs, GPs, and more, get real insights, and be part of a curated network built to help you grow. Apply now at ⁠www.bestevercommunity.com⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of Digging Deep, MG and Luis celebrate hitting episode four and reflect on Luis' journey through his first 68 days at OKIE811. From mastering presentations in a second language to learning the nuances of excavation terminology, Luis shares how practice and mentorship have helped him grow. The duo also recaps a busy week, including MG's appearance on the news, a successful golf tournament with industry partners, and preparations for upcoming presentations and events like the Ada Safety Day and Virtual Safety Day. They dive into key safety topics such as private lines, update tickets, and emergency locate requests—all while keeping things fun with sports talk and some friendly Thunder banter. This episode offers a great mix of education, encouragement, and laughs as Luis continues his path toward becoming a certified 811 pro.

In this episode, you get to explore the nuances within the power in your presence as a ManiGen. Deep reflections will come from this, make sure you DM me your reflections from the episode on IG. I'd love to hear!  with massive love,-C Welcome to the world of The Embodied MG, I'm here to expand every inch of your MG magic. Say goodbye to shoulds, conditioning, and limitations and create success that feels like freedom. Excited to have you here. If you love the show, if my work is of value to you please help me spread the work and leave us a 5-star review, tag me on IG when you listen, and share your fav episodes with your favorite friends. SPECIAL OFFER: being & receiving: 30-days to fill in the steps you missed.WebsiteThe First Hit: Catch the Signal, Move at MG Speed (Free Telegram Group)Follow on InstagramWebsiteThe Embodied MG on YouTube

We are baaack! Hey babe, Caroline here. Evolution is upon the podcast and here's what's happening, how I'm navigating it as an MG, and the big anchoring aspects of my work with The Embodied MG in the world. Wanna embody your magic deeper? Then this episode is one you don't want to miss. Here's to being all of you, more of you, and living a life beyond alllll our dreams,-CLinks mentioned in this episode:The EbookThe 30-day ProgramEffortless ManifestationThe 1:1 intensiveThe free Telegram Channel Welcome to the world of The Embodied MG, I'm here to expand every inch of your MG magic. Say goodbye to shoulds, conditioning, and limitations and create success that feels like freedom. Excited to have you here. If you love the show, if my work is of value to you please help me spread the work and leave us a 5-star review, tag me on IG when you listen, and share your fav episodes with your favorite friends. SPECIAL OFFER: being & receiving: 30-days to fill in the steps you missed.WebsiteThe First Hit: Catch the Signal, Move at MG Speed (Free Telegram Group)Follow on InstagramWebsiteThe Embodied MG on YouTube

Mgła "Exercises In Futility"Robbie Basho "The Grain & The Lotus"Current 93 "The Mystical Body of Christ..."Kyrian's Circle "Kun Puhu Myrskyn Henki"Trees "Ashes"Deathspell Omega "Carnal Malefactor" 

Send us a textWelcome to  Podcast 228 on 28thof June, 2025: This week's 10 outstanding high dividend stocks are in the attached podcast's narration and transcript. 5 U.S STOCK SELCTORS USED (1) common shares (2) dividend yield + 5% (3) # shares traded over 1M price gain +1%. QUALIFIERS' STOCK SYMBOLS & THEIR SCORES: (1) APAM Score 47(2) CPA Score 68 (3) MSB Score 44 (4) NVEC Score 56  (5) ITRN Score 55.5 CANADIAN STOCK SELCTORS (1) common shares (2) dividend yield + 5% (3) # shares traded over 51K (4) operating margins +3% (5) share prices $12.00 (6) weekly share price gain +1%. QUALIFIERS' & SCORES   (1) TRP Score 71 (2) RCI.B Score 60 (3) MG Score 65 (4)  CCA Score 64 (5) SIA Score 45.  DATA USED FOR ALL STOCK SCORE CALCULATIONS:   (1) Price $ (2)  Price 4yrs ago $ (3) Book Value $ (4) Advisor Buys # (5) Advisor Strong Buys # (6) Dividend. Yield % (7)Operating Margin % (8) Share Volume Traded # (9) Price/Earnings Ratio.     CNADIAN SCORE  CALCULATIONS (K=thousand M=million)STOCK  1            2           3     4   5     6          7          8       9TRP |67.00| 56.14 |26.55 |8|0| 5.07| 43.84| 21M| 17.5xRCI.B |39.87| 66.27| 19.40| 5 |0| 5.02| 22.40| 1.5M |12.2x MG |52.76 114.92| 55.72| 3| 0 |5.14 4.13 | 2M| | 9.6x CCA  |69.23| 121.39 | 70.59| 4| 0 | 5.33 |27.88 |47K |8.9x  SIA |18.79 16.36 |5.82| 2 | 0 | 4.98| 9.40| 284K | 44.4xUS SCORE CALCULATIONS | APAM |44.55 | 51.03 | 4.84 | 1 |  0 | 6.11 |3 3.39| 1.3M| 12.3x| CPA | 108.04 | 74.65 | 57.63| 4 | 0 | 5.96 | 21.75 | 333K | 7.4x| MSB | 24.99 | 36.00 | 1.78 | 0 | 0 | 28.81 |96.23| 82K | 3.5x| NVEC | 74.03 | 73.41 |12.87 | 0  | 0 | 5.40 | 61.81 | 169K | 23.8x| ITRN | 37.75 | 26.90 | 7.89 | 1 | 0 | 5.30 | 21.56 | 63K | 13.6xFor information on  my 6 investment books go to  www.informus.ca.  Ian Duncan MacDonaldAuthor, Artist, Commercial Risk Consultant,President of Informus Inc 2 Vista Humber Drive Toronto, Ontario Canada, M9P 3R7 Toronto Telephone - 416-245-4994 New York Telephone - 929-800-2397 imacd@informus.ca

Dr. Diwakar Davar and Dr. Jason Luke discuss novel agents in melanoma and other promising new data in the field of immunotherapy that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Diwakar Davar: Hello. My name is Diwakar Davar, and I am welcoming you to the ASCO Daily News Podcast. I'm an associate professor of medicine and the clinical director of the Melanoma and Skin Cancer Program at the University of Pittsburgh's Hillman Cancer Center. Today, I'm joined by my colleague and good friend, Dr. Jason Luke. Dr. Luke is a professor of medicine. He is also the associate director of clinical research and the director of the Phase 1 IDDC Program at the University of Pittsburgh's Hillman Cancer Center. He and I are going to be discussing some key advancements in melanoma and skin cancers that were presented at the 2025 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode.  Jason, it is great to have you back on the podcast. Dr. Jason Luke: Thanks again so much for the opportunity, and I'm really looking forward to it. Dr. Diwakar Davar: Perfect. So we will go ahead and start talking a little bit about a couple of key abstracts in both the drug development immunotherapy space and the melanoma space. The first couple of abstracts, the first two, will cover melanoma. So, the first is LBA9500, which was essentially the primary results of RELATIVITY-098. RELATIVITY-098 was a phase 3 trial that compared nivolumab plus relatlimab in a fixed-dose combination against nivolumab alone for the adjuvant treatment of resected high-risk disease. Jason, do you want to maybe give us a brief context of what this is? Dr. Jason Luke: Yeah, it's great, thanks. So as almost all listeners, of course, will be aware, the use of anti–PD-1 immunotherapies really revolutionized melanoma oncology over the last 10 to 15 years. And it has become a standard of care in the adjuvant setting as well. But to review, in patients with stage III melanoma, treatment can be targeted towards BRAF with BRAF and MEK combination therapy, where that's relevant, or anti–PD-1 with nivolumab or pembrolizumab are a standard of care. And more recently, we've had the development of neoadjuvant approaches for palpable stage III disease. And in that space, if patients present, based on two different studies, either pembrolizumab or nivolumab plus ipilimumab can be given prior to surgery for somewhere in the 6- to 9-week range. And so all of these therapies have improved time-to-event endpoints, such as relapse-free or event-free survival. It's worth noting, however, that despite those advances, we've had a couple different trials now that have actually failed in this adjuvant setting, most high profile being the CheckMate-915 study, which looked at nivolumab plus ipilimumab and unfortunately was a negative study. So, with RELATIVITY-047, which was the trial of nivolumab plus relatlimab that showed an improvement in progression-free survival for metastatic disease, there's a lot of interest, and we've been awaiting these data for a long time for RELATIVITY-098, which, of course, is this adjuvant trial of LAG-3 blockade with relatlimab plus nivolumab. Dr. Diwakar Davar: Great. So with that, let's briefly discuss the trial design and the results. So this was a randomized, phase 3, blinded study, so double-blinded, so neither the investigators knew what the patients were getting, nor did the patients know what they were getting. The treatment investigational arm was nivolumab plus relatlimab in the fixed-dose combination. So that's the nivolumab standard fixed dose with relatlimab that was FDA approved in RELATIVITY-047. And the control arm was nivolumab by itself. The duration of treatment was 1 year. The patient population consisted of resected high-risk stage III or IV patients. The primary endpoint was investigator-assessed RFS. Stage and geography were the standard stratifying factors, and they were included, and most of the criteria were balanced across both arms. What we know at this point is that the 2-year RFS rate was 64% and 62% in the nivolumab and nivolumab-combination arms, respectively. The 2-year DMFS rate was similarly equivalent: 76% with nivolumab monotherapy, 73% with the combination. And similar to what you had talked about with CheckMate 915, unfortunately, the addition of LAG-3 did not appear to improve the RFS or DMFS compared to control in this patient population. So, tell us a little bit about your take on this and what do you think might be the reasons why this trial was negative? Dr. Jason Luke: It's really unfortunate that we have this negative phase 3 trial. There had been a lot of hope that the combination of nivolumab with relatlimab would be a better tolerated combination that increased the efficacy. So in the metastatic setting, we do have 047, the study that demonstrated nivolumab plus relatlimab, but now we have this negative trial in the adjuvant setting. And so as to why exactly, I think is a complicated scenario. You know, when we look at the hazard ratios for relapse-free survival, the primary endpoint, as well as the secondary endpoints for distant metastasis-free survival, we see that the hazard ratio is approximately 1. So there's basically no difference. And that really suggests that relatlimab in this setting had no impact whatsoever on therapeutic outcomes in terms of efficacy. Now, it's worth noting that there was a biomarker subanalysis that was presented in conjunction with these data that looked at some immunophenotyping, both from circulating T cells, CD8 T cells, as well as from the tumor microenvironment from patients who were treated, both in the previous metastatic trial, the RELATIVITY-047 study, and now in this adjuvant study in the RELATIVITY-098 study. And to briefly summarize those, what was identified was that T cells in advanced melanoma seemed to have higher expression levels of LAG-3 relative to T cells that are circulating in patients that are in the adjuvant setting. In addition to that, there was a suggestion that the magnitude of increase is greater in the advanced setting versus adjuvant. And the overall summary of this is that the suggested rationale for why this was a negative trial may have been that the target of LAG-3 is not expressed as highly in the adjuvant setting as it is in the metastatic setting. And so while the data that were presented, I think, support this kind of an idea, I am a little bit cautious that this is actually the reason for why the trial was negative, however. I would say we're not really sure yet as to why the trial was negative, but the fact that the hazard ratios for the major endpoints were essentially 1 suggests that there was no impact whatsoever from relatlimab. And this really makes one wonder whether or not building on anti–PD-1 in the adjuvant setting is feasible because anti–PD-1 works so well. You would think that even if the levels of LAG-3 expression were slightly different, you would have seen a trend in one direction or another by adding a second drug, relatlimab, in this scenario. So overall, I think it's an unfortunate circumstance that the trial is negative. Clearly there's going to be no role for relatlimab in the adjuvant setting. I think this really makes one wonder about the utility of LAG-3 blockade and how powerful it really can be. I think it's probably worth pointing out there's another adjuvant trial ongoing now of a different PD-1 and LAG-3 combination, and that's cemiplimab plus fianlimab, a LAG-3 antibody that's being dosed from another trial sponsor at a much higher dose, and perhaps that may make some level of difference. But certainly, these are unfortunate results that will not advance the field beyond where we were at already. Dr. Diwakar Davar: And to your point about third-generation checkpoint factors that were negative, I guess it's probably worth noting that a trial that you were involved with, KeyVibe-010, that evaluated the PD-1 TIGIT co-formulation of vibostolimab, MK-4280A, was also, unfortunately, similarly negative. So, to your point, it's not clear that all these third-generation receptors are necessarily going to have the same impact in the adjuvant setting, even if they, you know, for example, like TIGIT, and they sometimes may not even have an effect at all in the advanced cancer setting. So, we'll see what the HARMONY phase 3 trial, that's the Regeneron cemiplimab/fianlimab versus pembrolizumab control with cemiplimab with fianlimab at two different doses, we'll see how that reads out. But certainly, as you've said, LAG-3 does not, unfortunately, appear to have an impact in the adjuvant setting. So let's move on to LBA9501. This is the primary analysis of EORTC-2139-MG or the Columbus-AD trial. This was a randomized trial of encorafenib and binimetinib, which we will abbreviate as enco-bini going forward, compared to placebo in high-risk stage II setting in melanoma in patients with BRAF V600E or K mutant disease. So Jason, you know, you happen to know one or two things about the resected stage II setting, so maybe contextualize the stage II setting for us based on the trials that you've led, KEYNOTE-716, as well as CheckMate-76K, set us up to talk about Columbus-AD. Dr. Jason Luke: Thanks for that introduction, and certainly stage II disease has been something I've worked a lot on. The rationale for that has been that building off of the activity of anti–PD-1 in metastatic melanoma and then seeing the activity in stage III, like we just talked about, it was a curious circumstance that dating back about 7 to 8 years ago, there was no availability to use anti–PD-1 for high-risk stage II patients, even though the risk of recurrence and death from melanoma in the context of stage IIB and IIC melanoma is in fact similar or actually higher than in stage IIIA or IIIB, where anti–PD-1 was approved. And in that context, a couple of different trials that you alluded to, the Keynote-716 study that I led, as well as the CheckMate 76K trial, evaluated pembrolizumab and nivolumab, respectively, showing an improvement in relapse-free and distant metastasis-free survival, and both of those agents have subsequently been approved for use in the adjuvant setting by the US FDA as well as the European Medicines Agency.  So bringing then to this abstract, throughout melanoma oncology, we've seen that the impact of anti–PD-1 immunotherapy versus BRAF and MEK-targeted therapy have had very similar outcomes on a sort of comparison basis, both in frontline metastatic and then in adjuvant setting. So it was a totally reasonable question to ask: Could we use adjuvant BRAF and MEK inhibitor therapy? And I think all of us expected the answer would be yes. As we get into the discussion of the trial, I think the unfortunate circumstance was that the timing of this clinical trial being delayed somewhat, unfortunately, made it very difficult to accrue the trial, and so we're going to have to try to read through the tea leaves sort of, based on only a partially complete data set. Dr. Diwakar Davar: So, in terms of the results, they wanted to enroll 815 patients, they only enrolled 110. The RFS and DMFS were marginally improved in the treatment arm but certainly not significantly, which is not surprising because the trial had only accrued 16% to 18% of its complete accrual. As such, we really can't abstract from the stage III COMBI-AD data to stage II patients. And certainly in this setting, one would argue that the primary treatment options certainly remain either anti–PD-1 monotherapy, either with pembrolizumab or nivolumab, based on 716 or 76K, or potentially active surveillance for the patients who are not inclined to get treated.  Can you tell us a little bit about how you foresee drug development going forward in this space because, you know, for example, with HARMONY, certainly IIC disease is a part of HARMONY. We will know at least a little bit about that in this space. So what do you think about the stage IIB/C patient population? Is this a patient population in which future combinations are going to be helpful, and how would you think about where we can go forward from here? Dr. Jason Luke: It is an unfortunate circumstance that this trial could not be accrued at the pace that was necessary. I think all of us believe that the results would have been positive if they'd been able to accrue the trial. In the preliminary data set that they did disclose of that 110 patients, you know, it's clear there is a difference at a, you know, a landmark at a year. They showed a 16% difference, and that would be in line with what has been seen in stage III. And so, you know, I think it's really kind of too bad. There's really going to be no regulatory approach for this consideration. So using BRAF and MEK inhibition in stage II is not going to be part of standard practice moving into the future. To your point, though, about where will the field go? I think what we're already realizing is that in the adjuvant setting, we're really overtreating the total population. And so beyond merely staging by AJCC criteria, we need to move to biomarker selection to help inform which patients truly need the treatment. And in that regard, I don't think we've crystallized together as a field as yet, but the kinds of things that people are thinking about are the integration of molecular biomarkers like ctDNA. When it's positive, it can be very helpful, but in melanoma, we found that, unfortunately, the rates are quite low, you know, in the 10% to 15% range in the adjuvant setting. So then another consideration would be factors in the primary tumor, such as gene expression profiling or other considerations.  And so I think the future of adjuvant clinical trials will be an integration of both the standard AJCC staging system as well as some kind of overlaid molecular biomarker that helps to enrich for a higher-risk population of patients because on a high level, when you abstract out, it's just clearly the case that we're rather substantially overtreating the totality of the population, especially given that in all of our adjuvant studies to date for anti–PD-1, we have not yet shown that there's an overall survival advantage. And so some are even arguing perhaps we should even reserve treatment until patients progress. I think that's a complicated subject, and standard of care at this point is to offer adjuvant therapy, but certainly a lot more to do because many patients, you know, unfortunately, still do progress and move on to metastatic disease. Dr. Diwakar Davar: Let's transition to Abstract 2508. So we're moving on from the melanoma to the novel immunotherapy abstracts. And this is a very, very, very fascinating drug. It's IMA203. So Abstract 2508 is a phase 1 clinical update of IMA203. IMA203 is an autologous TCR-T construct targeting PRAME in patients with heavily pretreated PD-1-refractory metastatic melanoma. So Jason, in the PD-1 and CTLA-4-refractory settings, treatment options are either autologous TIL, response rate, you know, ballpark 29% to 31%, oncolytic viral therapy, RP1 with nivolumab, ORR about 30-ish percent. So new options are needed. Can you tell us a little bit about IMA203? Perhaps tell us for the audience, what is the difference between a TCR-T and traditional autologous TIL? And a little bit about this drug, IMA203, and how it distinguishes itself from the competing TIL products in the landscape. Dr. Jason Luke: I'm extremely enthusiastic about IMA203. I think that it really has transformative potential based on these results and hopefully from the phase 3 trial that's open to accrual now. So, what is IMA203? We said it's a TCR-T cell product. So what that means is that T cells are removed from a patient, and then they can be transduced through various technologies, but inserted into those T cells, we can then add a T-cell receptor that's very specific to a single antigen, and in this case, it's PRAME. So that then is contrasted quite a bit from the TIL process, which includes a surgical resection of a tumor where T cells are removed, but they're not specific necessarily to the cancer, and they're grown up in the lab and then given to the patient. They're both adoptive cell transfer products, but they're very different. One is genetically modified, and the other one is not. And so the process for generating a TCR-T cell is that patients are required to have a new biomarker that some may not be familiar with, which is HLA profiling. So the T-cell receptor requires matching to the concomitant HLA for which the peptide is bound in. And so the classic one that is used in most oncology practices is A*02:01 because approximately 48% of Caucasians have A*02:01, and the frequency of HLA in other ethnicities starts to become highly variable. But in patients who are identified to have A*02:01 genotype, we can then remove blood via leukapheresis or an apheresis product, and then insert via lentiviral transduction this T-cell receptor targeting PRAME. Patients are then brought back to the hospital where they can receive lymphodepleting chemotherapy and then receive the reinfusion of the TCR-T cells. Again, in contrast with the TIL process, however, these T cells are extremely potent, and we do not need to give high-dose interleukin-2, which is administered in the context of TIL. Given that process, we have this clinical trial in front of us now, and at ASCO, the update was from the phase 1 study, which was looking at IMA203 in an efficacy population of melanoma patients who were refractory at checkpoint blockade and actually multiple lines of therapy. So here, there were 33 patients and a response rate of approximately 50% was observed in this population of patients, notably with a duration of response approximately a year in that treatment group. And I realize that these were heavily pretreated patients who had a range of very high-risk features. And approximately half the population had uveal melanoma, which people may be aware is a generally speaking more difficult-to-treat subtype of melanoma that metastasizes to the liver, which again has been a site of resistance to cancer immunotherapy. So these results are extremely promising. To summarize them from what I said, it's easier to make TCR-T cells because we can remove blood from the patient to transduce the T cells, and we don't have to put them through surgery. We can then infuse them, and based on these results, it looks like the response rate to IMA203 is a little bit more than double what we expect from lifileucel. And then, whereas with lifileucel or TILs, we have to give high-dose IL-2, here we do not have to give high-dose IL-2. And so that's pretty promising. And a clinical trial is ongoing now called the SUPREME phase 3 clinical trial, which is hoping to validate these results in a randomized global study. Dr. Diwakar Davar: Now, one thing that I wanted to go over with you, because you know this trial particularly well, is what you think of the likelihood of success, and then we'll talk a little bit about the trial design. But in your mind, do you think that this is a trial that has got a reasonable likelihood of success, maybe even a high likelihood of success? And maybe let's contextualize that to say an alternative trial, such as, for example, the TebeAM trial, which is essentially a T-cell bispecific targeting GP100. It's being compared against SOC, investigator's choice control, also in a similarly heavily pretreated patient population. Dr. Jason Luke: So both trials, I think, have a strong chance of success. They are very different kinds of agents. And so the CD3 bispecific that you referred to, tebentafusp, likely has an effect of delaying progression, which in patients with advanced disease could have a value that might manifest as overall survival. With TCR-T cells, by contrast, we see a very high response rate with some of the patients going into very durable long-term benefit. And so I do think that the SUPREME clinical trial has a very high chance of success. It will be the first clinical trial in solid tumor oncology randomizing patients to receive a cell therapy as compared with a standard of care. And within that standard of care control arm, TILs are allowed as a treatment. And so it will also be the first study that will compare TCR-T cells against TILs in a randomized phase 3. But going back to the data that we've seen in the phase 1 trial, what we observe is that the duration of response is really connected to the quality of the response, meaning if you have more than a 50% tumor shrinkage, those patients do very, very well. But even in patients who have less than 50% tumor shrinkage, the median progression-free survival right now is about 4.5 months. And again, as we think about trial design, standard of care options for patients who are in this situation are unfortunately very bad. And the progression-free survival in that population is probably more like 2 months. So this is a trial that has a very high likelihood of being positive because the possibility of long-term response is there, but even for patients who don't get a durable response, they're likely going to benefit more than they would have based on standard chemotherapy or retreatment with an anti–PD-1 agent. Dr. Diwakar Davar: Really, a very important trial to enroll, a trial that is first in many ways. First of a new generation of TCR-T agents, first trial to look at cell therapy in the control arm, a new standard of efficacy, but potentially also if this trial is successful, it will also be a new standard of trial conduct, a new kind of trial, of a set of trials that will be done in the second-line immunotherapy-refractory space. So let's pivot to the last trial that we were going to discuss, which was Abstract 2501. Abstract 2501 is a first-in-human phase 1/2 trial evaluating BNT142, which is the first-in-class mRNA-encoded bispecific targeting Claudin-6 and CD3 in patients with Claudin-positive tumors. We'll talk a little bit about this, but maybe let's start by talking a little bit about Claudin-6. So Claudin-6 is a very interesting new target. It's a target that's highly expressed in GI and ovarian tumors. There are a whole plethora of Claudin-6-targeting agents, including T-cell bispecifics and Claudin-6-directed CAR-Ts that are being developed. But BNT142 is novel. It's a novel lipid nanoparticle LNP-encapsulated mRNA. The mRNA encodes an anti–Claudin-6 CD3 bispecific termed RiboMAB-021. And it then is administered to the patient. The BNT142-encoding mRNA LNPs are taken up by the liver and translated into the active drug. So Jason, tell us a little bit about this agent. Why you think it's novel, if you think it's novel, and let's talk a little bit then about the results. Dr. Jason Luke: So I certainly think this is a novel agent, and I think this is just the first of what will probably become a new paradigm in oncology drug development. And so you alluded to this, but just to rehash it quickly, the drug is encoded as genetic information that's placed in the lipid nanoparticle and then is infused into the patient. And after the lipid nanoparticles are taken up by the liver, which is the most common place that LNPs are usually taken up, that genetic material in the mRNA starts to be translated into the actual protein, and that protein is the drug. So this is in vivo generation, so the patient is making their own drug inside their body. I think it's a really, really interesting approach. So for any drug that could be encoded as a genetic sequence, and in this case, it's a bispecific, as you mentioned, CD3-Claudin-6 engager, this could have a tremendous impact on how we think about pharmacology and novel drug development moving into the future in oncology. So I think it's an extremely interesting drug, the like of which we'll probably see only more moving forward. Dr. Diwakar Davar: Let's maybe briefly talk about the results. You know, the patient population was heavily pretreated, 65 or so patients, mostly ovarian cancer. Two-thirds of the patients were ovarian cancer, the rest were germ cell and lung cancer patients. But let's talk a little bit about the efficacy. The disease control rate was about 58% in the phase 1 population as a whole, but 75% in the ovarian patient population. Now tell us a little bit about the interesting things about the drug in terms of the pharmacokinetics, and also then maybe we can pivot to the clinical activity by dose level. Dr. Jason Luke: Well, so they did present in their presentation at ASCO a proportionality showing that as higher doses were administered, that greater amounts of the drug were being made inside the patient. And so that's an interesting observation, and it's an important one, right? Suggesting that the pharmacology that we classically think of by administering drugs by IV, for example, would still be in play. And that did translate into some level of efficacy, particularly at the higher dose levels. Now, the caveat that I'll make a note of is that disease control rate is an endpoint that I think we have to be careful about because what that really means is sometimes a little bit unclear. Sometimes patients have slowly growing tumors and so on and so forth. And the clinical relevance of disease control, if it doesn't last at least 6 months, I think is probably pretty questionable. So I think these are extremely interesting data, and there's some preliminary sense that getting the dose up is going to matter because the treatment responses were mostly observed at the highest dose levels. There's also a caveat, however, that across the field of CD3 bispecific molecules like this, there's been quite a bit of heterogeneity in terms of the response rate, with some of them only really generating stable disease responses and other ones having more robust responses. And so I think this is a really interesting initial foray into this space. My best understanding is this molecule is not moving forward further after this, but I think that this really does set it up to be able to chase after multiple different drug targets on a CD3 bispecific backbone, both in ovarian cancer, but then basically across all of oncology. Dr. Diwakar Davar: Perfect. This is a very new sort of exciting arena where we're going to be looking at, in many ways, these programmable constructs, whether we're looking at in vivo-generated, in this case, a T-cell bispecific, but we've also got newer drugs where we are essentially giving drugs where people are generating in vivo CAR T, and also potentially even in vivo TCR-T. But certainly lots of new excitement around this entire class of drugs. And so, what we'd like to do at this point in time is switch to essentially the fact that we've got a very, very exciting set of data at ASCO 2025. You've heard from Dr. Luke regarding the advances in both early drug development but also in advanced cutaneous melanoma. And Jason, as always, thank you so much for sharing your very valuable and great, fantastic insights with us on the ASCO Daily News Podcast. Dr. Jason Luke: Well, thanks again for the opportunity. Dr. Diwakar Davar: And thank you to our listeners for taking your time to listen today. You will find the links to the abstracts that we discussed today in the transcript of this episode. And finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:    Dr. Diwakar Davar    @diwakardavar    Dr. Jason Luke @jasonlukemd Follow ASCO on social media:     @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn   Disclosures:     Dr. Diwakar Davar:      Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences     Consulting or Advisory Role: Instil Bio, Vedanta Biosciences     Consulting or Advisory Role (Immediate family member): Shionogi     Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences     Research Funding (Inst.): Zucero Therapeutics     Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy     Dr. Jason Luke:     Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical, Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX     Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine     Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure     Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)     Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio

O juiz Lourenço Migliorini Fonseca Ribeiro disse que não teve intenção de afrontar o STF ao determinar a soltura do homem responsável por quebrar o relógio de Dom João VI no 8 de janeiro.Segundo Lourenço, a decisão foi um "equívoco" de sua parte, cometido por causa de um erro de cadastramento.O juiz, da Vara de Execuções Penais de Uberlândia (MG),  prestou depoimento à Polícia Federal (PF) na segunda-feira, 23, no âmbito do inquérito instaurado, por ordem do ministro Alexandre de Moraes, do STF, para apurar a conduta dele no caso.Ao determinar a investigação, Moraes disse que o juiz "proferiu decisão fora do âmbito de sua competência, não havendo qualquer decisão desta Suprema Corte que tenha lhe atribuído a competência para qualquer medida a não ser a mera emissão do atestado de pena”.Felipe Moura Brasil e Wilson Lima comentam:Papo Antagonista é o programa que explica e debate os principais acontecimentos do   dia com análises críticas e aprofundadas sobre a política brasileira e seus bastidores.     Apresentado por Felipe Moura Brasil, o programa traz contexto e opinião sobre os temas mais quentes da atualidade.     Com foco em jornalismo, eleições e debate, é um espaço essencial para quem busca informação de qualidade.     Ao vivo de segunda a sexta-feira às 18h.    Apoie o jornalismo Vigilante: 10% de desconto para audiência do Papo Antagonista  https://bit.ly/papoantagonista  Siga O Antagonista no X:  https://x.com/o_antagonista   Acompanhe O Antagonista no canal do WhatsApp. Boletins diários, conteúdos exclusivos em vídeo e muito mais.  https://whatsapp.com/channel/0029Va2SurQHLHQbI5yJN344  Leia mais em www.oantagonista.com.br | www.crusoe.com.br 

MG - invitați Nicu Alifantis și Marcel Iureș

Confira nesta edição do JR 24 Horas: O premiê israelense Benjamin Netanyahi afirmou que o país destruiu pelo menos metade dos lançadores de mísseis iranianos. Segundo ele, o principal objetivo de Israel é impedir que o Irã tenha acesso a armas nucleares. O premiê também admitiu que a guerra pode levar a queda do regime do aiatolá Ali Khamenei. E ainda: Ministro Alexandre de Moraes manda investigar juiz Lourenço Ribeiro, de Uberlândia (MG). 

Do you have a relationship with the robot in your life? You'll fall in love with "The Wild Robot" by Peter Brown. 4th graders from Flora Hendley Elementary School in Washington, D.C. discuss artificial intelligence and their own favorite robotic devices. U.S. Congressman Scott Peters from San Diego is celebrity reader. Kitty Felde is host. Favorite Books from Flora Hendley Elemetary School: Diary of a Wimpy Kid - Jeff Kinney Dork Diaries- Rachel Renée Russell The True Story of the Three Little Pigs - Jon Scieszka Peter Brown's Favorite Book: The Hobbit - J. R. R. Tolkien Congressman Scott Peter's Favorite Book: East of Eden - John Steinbeck

MG - invitat Chestorul de poliție Cătălin-Aurel Giulescu

In this episode of the Human Design Hive Podcast, we're diving into the energy of the 5/2 profile. This one has a bit of a reputation. Equal parts leadership potential and leave-me-alone energy- and honestly, it makes sense why it can feel like such a strange ride sometimes.If you've ever felt pulled between wanting to make a difference and wanting to disappear entirely, the 5/2 profile might sound a little too familiar.Here's what we get into:- What the 5 and 2 lines actually represent (and why this combo can feel like being seen and unseen at the same time) - The unique tension between public projection and private hermiting- How to navigate the “call to lead” without burning out or blending in- How this profile shows up differently depending on your Human Design type (Generator, Projector, Manifestor, Reflector)- A few real-life 5/2s that might surprise you—and why they're great examples of this energy in actionTimestamps:00:00 Welcome01:26 Reflections on No Kings Day11:30 Intro to Profiles17:56 Profile Lines and House analogy19:47 Line 525:55 Line 233:32 Projections36:45 5/2 Generator and MG's40:38 5/2 Projector46:15 5/2 Manifestor47:52 5/2 Reflector50:06 5/2's in Real Life53:22 James McAvoy01:01:41 Robert DeNiro01:11:39 Ivanka Trump01:19:40 5/2 Wrap Up01:20:44 ICX of the WeekA few things to take with you:Just because others see something in you doesn't mean you have to say yes. The real power of the 5/2 comes from knowing yourself well enough to discern what's yours to lead—and what's just noise. Let your own clarity set the tone, not other people's expectations.Thanks for hanging out with us!Join the HDH podcast over on Substack! Get new episodes (and bonuses) delivered straight to your inbox!https://danaphillips.substack.com/Tired of fighting your own energy? The Energetic Clarity guidebook translates your Human Design into practical wisdom so you can stop forcing what doesn't work and start living what does. Grab yours here:https://www.humandesignhive.com/guidebookWant insight on your design, on your time? Check out the customized Audio Human Design Reading: https://www.humandesignhive.com/audio_readingGrab your FREE copy of your Human Design chart (Bodygraph) Here: https://www.humandesignhive.com/freechartReady to gain clarity on your Human Design with Dana?Book a Clarity Session now! https://cal.com/DanaHDHNeed some Human Design informed intuitive guidance? Check out my Email Intuitive Reading offer!https://humandesignhive.com/EmailReadingFollow Dana on IG: Instagram (@humandesignhive)Website: https://www.humandesignhive.comemail: Dana@humandesignhive.com This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit danaphillips.substack.com/subscribe

MG - 17.06.2025

MG - 16.06.2025

Mason and Ireland are both out today, so Marcas Grant and Brian Kamenetzky are in! BK and MG go on a twin tangent. Who in the NBA world had a rap track? Will the Dodgers make it out of their next stretch of games still in first place? Game of Games, plus Supercross Talk! Learn more about your ad choices. Visit podcastchoices.com/adchoices

In this episode of Leadership on the Links, we sit down with Brian Stiehler, CGCS, MG, to explore a career rooted in tradition and elevated through leadership. From his early days in Reading, PA, to impactful stints at Oakmont, Augusta, and St. Andrews, Brian shares how these formative experiences shaped his professional path—and how he's applied those lessons at Highlands Country Club for over two decades. What You'll Learn in This Episode: How working at Oakmont inspired Brian's leadership philosophy and set a new bar for professionalism What it's like managing an agronomy operation at 4,100 feet in the mountains of North Carolina How Brian and the Carolinas GCSA turned crisis into opportunity during the pandemic with innovative virtual education Insights into Oakmont's continued evolution ahead of the U.S. Open—and the lasting pride it instills in its alumni Whether you're a rising turf leader or a seasoned superintendent, Brian's story offers tactical wisdom, historical perspective, and a clear reminder of the importance of mentorship, structure, and community in our industry.  

Os repórteres do ge Gabriel Girardon e Tomás Hammes e o Voz da Torcida Luka Pumes mostram a preocupação dos colorados com a derrota para o Atlético-MG por 2 a 0 e a consequência de ficar o mês inteiro da parada para o Mundial de Clubes no Z-4 do Brasileirão. Dê o play e ouça!

Pain-point marketing is often very clear, but manipulation through triggering shame, not so much. Here's how to tell if you're confusing your sacral yes with shame being activated, ManiGen. being & receiving: 30-days to fill in the steps you missed.WebsiteThe First Hit: Catch the Signal, Move at MG Speed (Free Telegram Group)Welcome to the world of The Embodied MG, I'm here to expand every inch of your MG magic. Say goodbye to shoulds, conditioning, and limitations and create success that feels like freedom. Excited to have you here. If you love the show, please leave us a 5-star review. Follow on InstagramWebsiteThe Embodied MG on YouTube

There are a lot of reasons ManiGens buy things. One big reason is their shame. Here are 5 signs the sales page, content, offer has triggered your shame and isn't a sacral yes decision, MG. being & receiving: 30-days to fill in the steps you missed.WebsiteThe First Hit: Catch the Signal, Move at MG Speed (Free Telegram Group)Welcome to the world of The Embodied MG, I'm here to expand every inch of your MG magic. Say goodbye to shoulds, conditioning, and limitations and create success that feels like freedom. Excited to have you here. If you love the show, please leave us a 5-star review. Follow on InstagramWebsiteThe Embodied MG on YouTube

MG - invitați Călin Goia și Alina Eremia

Hey there! In this episode of the Human Design Hive Podcast, we're digging into the 4/6 profile—one of the more layered and quietly powerful profiles in Human Design. If you (or someone you love) is a 4/6, this one's for you.We talk about what makes the 4/6 so unique, why it's considered a "personal" profile even though both numbers live in the upper trigram, and what it really looks like to lead from embodied wisdom.In this episode, you'll hear:-What the 4 and 6 lines actually feel like in daily life - Why the early part of life can feel bumpy for 4/6s (hint: relationships + trial and error = lessons) - How 4/6s build influence through personal connection, not performance - Real examples of well-known 4/6s living their design - How this profile shows up in each energy type—Generator, Projector, Manifestor, and Reflector We wrap things up with the Incarnation Cross of the Week and a few laughs, as always. So whether you're a 4/6 navigating your own path, or just curious how this profile plays out, you'll come away with new insights—and probably a couple “that's so me!” moments.Timestamps:00:00 Welcome and chitchat05:03 Intro to Profiles10:22 Intro to 4/6 Profile11:16 House Analogy16:00 The 4/6 Anomaly16:46 Line 420:57 Line 624:38 Not Harmonious Pairing32:17 Embodied Leadership32:40 Why a RAX?36:56 4/6 purpose39:18 Challenges for 4/640:24 4/6 Generators and MG's42:22 4/6 Projector46:30 4/6 Manifestor48:03 4/6 Reflector52:31 Sir David Attenborough01:00:41 Lisa Rinna01:05:45 Christina Applegate01:12:34 4/6 Wrap Up01:13:36 ICX of the WeekTired of fighting your own energy? The Energetic Clarity guidebook translates your Human Design into practical wisdom so you can stop forcing what doesn't work and start living what does. Grab yours here: https://www.humandesignhive.com/guidebookReady to gain clarity on your Human Design with Dana? Book a Clarity Session now! https://cal.com/DanaHDHJoin the HDH podcast over on Substack! Get new episodes (and bonuses) delivered straight to your inbox! https://danaphillips.substack.com/Want insight on your design, on your time? Check out the customized Audio Human Design Reading: https://www.humandesignhive.com/audio_readingGrab your FREE copy of your Human Design chart (Bodygraph) Here: https://www.humandesignhive.com/freechartFollow Dana on IG: Instagram (@humandesignhive)Website: https://www.humandesignhive.comemail: Dana@humandesignhive.com This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit danaphillips.substack.com/subscribe

MG - invitați Andreea Esca, Mihaela Geoană & Dr. Mihai Craiu

MG - invitați instructorul de înot Sebastian Furtună & Dana Rogoz

This visual Manifesting Generator Masterclass (filmed in 2022) unpacks the unique hybrid energy of the MG: equal parts sacral powerhouse & fast-moving creator. In this class, we explore how MGs operate differently from Generators, while also honoring their shared traits.Expect an in-depth look at Manifesting Generator strategy, authority, common conditioning traps, and how to move from chaos to clarity.Learn to embrace your nonlinear path, recognize frustration and anger, and master the art of pivoting without shame.This episode is ideal for MGs looking to reconnect with their joy, speed, and sacred “yes,” and for anyone supporting an MG in their life.Work with me or find more resources at mikaelamaclean.comInstagram: @mikaelamacleanMusic by Lofi Hour “Empty Mind”

MG - invitat Ștefan Nanu (Trezoreria României)

Mignonne Gavigan launched in 2014. It was a bit spontaneous. Mignonne, "Maggie", was experimenting with a beaded couture vintage gown and an embellished piece of fabric fell to the floor. She picked it up and fastened it around her neck because she thought it was a cool scarf vibe. On her walk home through Soho a handful of compliments and questions on where she had gotten her necklace came about and the first Mignonne Gavigan design idea was born. She always knew she wanted to create a brand, a community and a workplace that were all built on kindness and happiness. Maggie launched Mignonne Gavigan jewelry in hopes that each piece would bring joy and happiness to the wearer. Ultimately what she's discovered is that women develop a significant amount of confidence when wearing an MG piece. That is so important to the MG team- that we are building a community of confident and joy-filled women.https://mignonnegavigan.com/ 

On this episode the gang heads to the stables and finds Don a talking horse and the star of this 1988 movie "Hot to Trot" They wonder why anyone would want to have fun with your partner in the stables. They talk about Mr. Ed and not surprisingly the young ones didn't know what show that was. Hannah shows off her 3 Stooges shirt. Plus the topic of bath bombs gets brought up and MTD is disgusted that his son wants to make bath bombs. Brad talks about wanting a hot tub and Jacob says he would sit in the hot tub with Brad as long as it's spacious. Jets and space are always needed. Brad also brings up the fact that when they go to Ashley's for a meet up will she allow MG to be there. Mazel Mazel..Checkout the new Hopecast website:https://thehopecastnetwork.com/Follow Movie Torture here:https://www.instagram.com/movietorturepod/Buy Merch here:https://www.bonfire.com/store/the-hopecast-network-swag/This show is brought to you by The Hopecast Networkhttps://www.instagram.com/hopecastnetwork/

Se o povo não tem pão, então que comam brioches! Separe trinta minutos do seu dia e aprenda com o professor Vítor Soares (@profvitorsoares) sobre a vida e a trajetória de Maria Antonieta.-Se você quiser ter acesso a episódios exclusivos e quiser ajudar o História em Meia Hora a continuar de pé, clique no link: www.apoia.se/historiaemmeiahoraConheça o meu canal no YouTube, e assista o História em Dez Minutos!https://www.youtube.com/@profvitorsoaresOuça "Reinaldo Jaqueline", meu podcast de humor sobre cinema e TV:https://open.spotify.com/show/2MsTGRXkgN5k0gBBRDV4okCompre o livro "História em Meia Hora - Grandes Civilizações"!https://a.co/d/47ogz6QCompre meu primeiro livro-jogo de história do Brasil "O Porão":https://amzn.to/4a4HCO8Compre nossas camisas, moletons e muito mais coisas com temática História na Lolja!www.lolja.com.br/creators/historia-em-meia-hora/PIX e contato: historiaemmeiahora@gmail.comApresentação: Prof. Vítor Soares.Roteiro: Prof. Vítor Soares e Prof. Victor Alexandre (@profvictoralexandre)REFERÊNCIAS USADAS:- GOEBEL, Felipe. As ressignificações de Maria Antonieta no século XIX: de bode expiatório a rainha mártir a modelo a ser seguido. - MARÇAL,Emanuelle Amaral Almeida. “Marie Antoinette C'est moi”: Reflexões em torno do romance biográfico Maria Antonieta, de Stefan Zweig. Universidade Federal de Uberlândia/MG

Now that Primo is no longer available, will Equipoise be the next go-to steroid to control estrogen? Plus Steroid QA Drugs N Stuff Podcast - Dave Crosland & Scott McNally 0:00 Tren soldiers 0:40 Intro 3:00 Equipoise to control estrogen? 7:00 test conversion vs equipoise conversion 8:15 Test to EQ ratios 9:50 Estrogen and hematocrit 12:30 figuring out how well EQ controls estrogen for YOU 16:10 Prostate Cancer Awareness Event 18:30 Dbol making you feel sick? 21:00 What can you run for joint issues? 24:00 Test & Mast vs Test at same total Mg? 30:45 Removing test and using Dbol for estrogen 33:30 Statin to Control Cholesterol? 37:30 Cycle for Older guy with THREE orals? 39:50 Getting Bloods done at FitExpo 42:45 How important is ester weight 47:25 Minimal amount to cycle? 52:20 Steroid Use and Donating Blood 55:30 Dave's Car Talk 1:03:30 Operator Syndrome and gear in the military

Erin Claire Jones is one of the world's leading experts in Human Design and she's back on the podcast for a conversation that goes way beyond the chart. Natalie and Erin dive deep into what it really looks like to birth a book and a baby at the same time, navigating business launches with limited time, and learning how to work with (not against) your natural energy. Whether you're a Generator trying to find balance, a Manifesting Generator embracing your multi-passionate nature, or just curious about how Human Design can support your parenting, this episode is packed with powerful insights. Erin also breaks down how each type - Generator, MG, Projector, Manifestor + Reflector - can approach launches, decisions, and daily life in a more aligned way. If you're ready to confidently make decisions that align with your goals, in both business and life, this episode is a must-listen. TIMESTAMPS 00:00 The story behind Erin's new book (and how it came to life postpartum) 02:00 What launching a book with a baby + toddler actually looks like 04:30 When to go hard, and when to scale back in a launch season 06:10 How Erin's Human Design as a Projector impacts her work style 10:15 A breakdown of the 5 Human Design types and how each launches differently 13:00 Why parenting and business both require constant recalibration 14:00 A powerful tip for Generators: community = opportunity 16:20 What it means to be “invited” as a Projector (and how to still pitch) 19:00 How Natalie + Erin parent through the lens of Human Design 23:00 How to use the book as a real-time guide for decisions and relationships 25:00 What's next for Erin post-launch (and what rest really looks like) RESOURCES + LINKS Erin's Book, How Do You Choose: A Human Design Guide To What's Best For You At Work, In Love, And In Life, Is Available Now! Get It Here. Get Your Personalized Human Design Blueprint Here. (Use Code BOSSBABE For A Discount) Become Human Design Coaching Certified With Erin Here. (Use Code BOSSBABE For A Discount) Sign Up For Our Free Weekly Newsletter & Get Insights From Natalie Every Single Week On All Things Strategy, Motherhood, Business Growth + More.  Drop Us A Review On The Podcast + Send Us A Screenshot & We'll Send You Natalie's 7-Figure Operating System Completely FREE (value $1,997).